Specific Combination Therapies Reduce Hospitalization Risk After Lithium Failure

Navigating the Maintenance Gap in Bipolar Disorder

Lithium remains the gold standard for maintenance therapy in bipolar disorder due to its established efficacy in preventing relapse and reducing suicide risk [1, 2]. However, clinical utility is often limited by poor tolerability, including a 1.85 relative risk of type 2 diabetes mellitus (95% CI: 1.45 to 2.37) in patients with severe mental illness and concerns regarding long-term cognitive impairment [3, 4]. While international guidelines recommend second-generation antipsychotics as alternatives, clinicians often face a lack of direct head-to-head data for maintenance strategies [5, 6, 7]. Transitioning patients requires maintaining high rates of treatment response while minimizing all-cause discontinuation (a measure of treatment acceptability that reflects both efficacy and tolerability), which varies significantly across pharmacological agents [8]. A new large-scale analysis now provides critical comparative effectiveness data for specific drug combinations in patients for whom lithium is no longer a viable option.

A Longitudinal Analysis of Real-World Maintenance

To evaluate the long-term efficacy of various pharmacological strategies, the researchers utilized data from two massive, harmonized nationwide cohorts. The study population included 105,495 patients from Sweden and 60,045 patients from Finland, providing a robust sample size for assessing real-world outcomes in bipolar disorder. These individuals were followed for an average of 9 years, a duration that allows for the observation of multiple treatment transitions and long-term stability patterns that are often missed in shorter clinical trials. This longitudinal design enabled the researchers to assess the comparative effectiveness of mood stabilizers, antipsychotics, and their combinations in a diverse, unselected clinical population. The study employed within-individual analyses, a statistical method where each patient serves as their own control to account for stable individual characteristics. By comparing the same person during periods of exposure to different medications, this approach effectively controls for fixed confounders (stable factors that could skew results) such as genetic predisposition, personality traits, and socioeconomic background. The primary outcome measured was the prevention of psychiatric hospitalization, which clinicians recognize as a critical proxy for severe relapse and a major driver of healthcare costs. By focusing on this objective endpoint, the findings provide a clear metric for which regimens most effectively maintain clinical stability in patients who have failed or discontinued standard therapy.

Clozapine and Long-Acting Injectables as High-Efficacy Alternatives

While lithium is the gold-standard maintenance treatment for bipolar disorder, clinicians frequently encounter patients who experience an inadequate response or intolerance to the medication. For these patients, identifying effective augmentation or replacement strategies is critical to preventing relapse. The researchers utilized within-individual analyses to compare various regimens against lithium monotherapy, focusing on their ability to prevent psychiatric hospitalization. The findings indicated that clozapine plus aripiprazole was associated with the lowest relapse risk among the studied combinations, yielding an adjusted hazard ratio of 0.42 (95% confidence interval, 0.22 to 0.80). This suggests a substantial reduction in the risk of hospitalization when this specific antipsychotic pairing is used compared to lithium alone. The study also highlighted the efficacy of clozapine as a standalone option and the benefits of utilizing long-acting formulations. When used as a monotherapy, clozapine alone was associated with a lower relapse risk than lithium monotherapy, with an adjusted hazard ratio of 0.61 (95% confidence interval, 0.49 to 0.75). Furthermore, for patients requiring combination therapy to maintain stability, the addition of long-acting injectable antipsychotics to lithium proved more effective than lithium monotherapy. Specifically, the combination of long-acting injectable antipsychotics plus lithium was associated with a lower relapse risk, demonstrated by an adjusted hazard ratio of 0.70 (95% confidence interval, 0.59 to 0.84). These data points provide clinicians with specific, high-efficacy alternatives for patients who do not achieve adequate stability on standard lithium protocols.

Pharmacological Strategies Following Lithium Discontinuation

For clinicians, the most challenging phase of maintenance therapy often begins when a patient must stop the gold-standard treatment due to side effects or lack of efficacy. The study specifically analyzed a subgroup of 20,645 lithium discontinuers to identify which regimens best prevent relapse after the medication is withdrawn. Among these patients, the most effective strategy for preventing psychiatric hospitalization was the combination of long-acting injectable antipsychotics plus valproate, which was linked to a significantly reduced hospitalization risk, demonstrated by an adjusted hazard ratio of 0.41 (95% confidence interval, 0.19 to 0.92). This finding suggests that for patients who cannot tolerate lithium, the use of a sustained-release antipsychotic paired with a traditional mood stabilizer provides the most robust protection against acute episodes. The researchers also identified several oral combination therapies that served as effective alternatives for the 20,645 patients who ceased lithium use. The combination of quetiapine plus lamotrigine was linked to a reduced hospitalization risk with an adjusted hazard ratio of 0.64 (95% confidence interval, 0.51 to 0.79). Similarly, regimens utilizing valproate as a backbone with second-generation antipsychotics showed consistent efficacy. Specifically, olanzapine plus valproate was linked to a reduced hospitalization risk (adjusted hazard ratio of 0.65; 95% confidence interval, 0.50 to 0.84), and risperidone plus valproate was linked to a reduced hospitalization risk (adjusted hazard ratio of 0.63; 95% confidence interval, 0.42 to 0.93). These findings identify specific regimens that provide evidence-based options for patients in whom lithium is ineffective or discontinued, allowing physicians to prioritize treatments with the strongest data-driven outcomes.

References

1. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018. doi:10.1111/bdi.12609

2. Cipriani A, Hawton K, Stockton S, Geddes J. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013. doi:10.1136/bmj.f3646

3. Leopold S, Quante A. [Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review].. Der Nervenarzt. 2023. doi:10.1007/s00115-023-01454-y

4. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis. World Psychiatry. 2016. doi:10.1002/wps.20309

5. Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Molecular Psychiatry. 2020. doi:10.1038/s41380-020-00946-6

6. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders. 2012. doi:10.1111/bdi.12025

7. Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis.. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2018. doi:10.1080/15622975.2017.1285050

8. Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry. 2021. doi:10.1038/s41380-021-01334-4